Clinica Baviera, SA (ES:CBAV)
BME:CBAV
Top Page
Clinica Baviera
(BME:CBAV)
Select Model
Select Model
Rating:67Neutral
Price Target:
€55.00
▲(16.28% Upside)
Action:DowngradedDate:03/07/26
The score is primarily supported by strong underlying fundamentals (steady growth, solid profitability, and positive operating cash flow). It is held back by weaker near-term technical momentum and a relatively high P/E, while the dividend yield offers partial valuation support.
Positive Factors
Specialized clinic network
Clinica Baviera's focused network model centers on elective refractive and broader ophthalmic services, producing fee-based revenues across diagnosis, surgery and follow-up care. That patient-pathway capture supports durable per-patient revenue, cross-selling and stable clinic utilization over time.
Negative Factors
Rising debt trend
An uptick in leverage into 2024–2025 reduces financial flexibility and raises sensitivity to slower growth or higher rates. Higher debt servicing obligations can limit discretionary investment, increase refinancing risk, and constrain strategic options if operating performance weakens over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized clinic network
Clinica Baviera's focused network model centers on elective refractive and broader ophthalmic services, producing fee-based revenues across diagnosis, surgery and follow-up care. That patient-pathway capture supports durable per-patient revenue, cross-selling and stable clinic utilization over time.
Read all positive factors
Clinica Baviera (CBAV) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€780.94M
Dividend Yield3.31%
Average Volume (3M)2.20K
Price to Earnings (P/E)15.3
Beta (1Y)0.52
Revenue GrowthN/A
EPS GrowthN/A
CountryES
Employees1,706
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.81
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.86
Revenue Forecast (FY)€323.25M
Clinica Baviera Business Overview & Revenue Model
Company Description
Clinica Baviera (CBAV) is a leading provider of ophthalmological services in Spain and several other countries, specializing in vision correction procedures such as LASIK and cataract surgery. The clinic operates a network of medical centers equip...
How the Company Makes Money
Clinica Baviera generates revenue primarily through its core services, including laser eye surgeries, cataract surgeries, and other ophthalmological treatments. The company charges patients for these procedures, which often involve significant fee...
Clinica Baviera Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 301.78M | 262.65M | 224.92M | 198.45M | 172.73M |
| Gross Profit | 60.54M | 232.08M | 197.85M | 172.95M | 151.25M |
| EBITDA | 84.53M | 78.11M | 67.22M | 56.15M | 53.49M |
| Net Income | 42.94M | 40.20M | 35.97M | 29.52M | 27.39M |
Balance Sheet | |||||
| Total Assets | 247.51M | 211.95M | 178.64M | 150.10M | 133.81M |
| Cash, Cash Equivalents and Short-Term Investments | 50.32M | 38.58M | 51.24M | 38.99M | 32.27M |
| Total Debt | 69.16M | 63.47M | 47.41M | 47.81M | 51.56M |
| Total Liabilities | 136.55M | 113.59M | 86.37M | 81.74M | 78.42M |
| Stockholders Equity | 109.99M | 96.92M | 91.00M | 67.34M | 54.60M |
Cash Flow | |||||
| Free Cash Flow | 46.47M | 36.25M | 35.13M | 39.35M | 36.28M |
| Operating Cash Flow | 76.48M | 62.76M | 57.81M | 53.38M | 46.86M |
| Investing Cash Flow | -27.88M | -20.90M | -44.31M | -12.56M | -17.08M |
| Financing Cash Flow | -36.10M | -39.91M | -24.37M | -31.45M | -30.80M |
Clinica Baviera Technical Analysis
Negative
47.30
Price Trends
51.23
Negative
49.08
Negative
46.13
Positive
Market Momentum
-0.92
Positive
38.46
Neutral
26.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Negative. The current price of 47.3 is below the 20-day moving average (MA) of 49.39, below the 50-day MA of 51.23, and above the 200-day MA of 46.13, indicating a neutral trend. The MACD of -0.92 indicates Positive momentum. The RSI at 38.46 is Neutral, neither overbought nor oversold. The STOCH value of 26.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ES:CBAV.
Clinica Baviera Peers Comparison
UnderperformOutperform
Sector (51)
ES:CBAV
Clinica Baviera
47.90
16.36
51.89%
ES:ALM
Almirall
12.32
3.45
38.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.